All articles by Frankie Fattorini

Frankie Fattorini

Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.

Podcast: Rare Disease Day: FDA guidance allowing advancement

It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
JPM26: 2025 a “breakout year” for rare disease biotechs

Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent…
FDA increases manufacturing flexibility for cell and gene therapies

The US Food and Drug Administration (FDA) has announced increased flexibility for cell and gene therapy (CGT) manufacturers, loosening quality…
Patient burden as an operational metric of clinical trial success

Patient burden should join standard operational metrics like cost, timelines, and regulatory compliance to ensure long-term clinical trial success, argues…

Collaboration with partners drives successful clinical trials, says Bayer exec

Closer relationships with clinical trial partners are key to ensuring long-term trial success with German pharma giant Bayer, says the…
AI to become as foundational as the internet in clinical trials, experts say

Artificial intelligence (AI) is expected to not only supplement clinical trials, but redefine the sector, while the industry braces for…
CTSWC25: The future of clinical trial supply hinges on risk management

Regulatory overhaul, international trade tariffs, and the burgeoning disruption imposed by artificial intelligence (AI) are moving the clinical trials industry…
Clinical trial supply chains in the US navigate pharma tariffs

Tariffs imposed by President Trump on US pharma imports have left experts charting a new course for the nation’s clinical…
Adapting to funding and operational hurdles in today’s clinical trials landscape

Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries,…